Hair Thinning on GLP-1s: What the Evidence Says

Aug 26

5 min read

Hair thinning on GLP-1 medications has moved well beyond anecdote — it's now the subject of multiple systematic reviews and real clinical trial data. Here's what the actual evidence says, rather than the more speculative claims that circulate online.

The trial data: this is a measurable effect, not just perception

In Wegovy's own clinical trial data, hair loss (alopecia) was reported in 3.3% of participants on semaglutide, compared with 1.4% on placebo — a relative risk of 2.38 (Sharma et al., 2025). Critically, the effect was dose-dependent on outcome, not just on medication: people who lost more than 20% of their body weight reported alopecia at a notably higher rate (5.3%) than those who lost less than 20% (2.5%) (Sharma et al., 2025).

A separate large-scale study published in The BMJ examined alopecia risk in people with type 2 diabetes taking GLP-1 medications compared with other diabetes drug classes, finding a 37% higher risk of alopecia versus SGLT-2 inhibitors, and a 68% higher risk versus DPP-4 inhibitors (Healthline, 2025).

What systematic reviews of the evidence actually conclude

Several independent systematic reviews have now synthesised the available evidence:

A 2026 systematic review screened 133 studies and included 24 that met its criteria, finding that semaglutide and tirzepatide specifically demonstrated the highest incidence rates of hair loss and the most frequent safety signals in pharmacovigilance data among GLP-1 medications (Gupta et al., 2026). The review found hair loss with semaglutide was dose-dependent — doses under 2 mg weekly (broadly the diabetes-treatment range) were rarely implicated, while the higher doses used for obesity treatment were far more commonly associated with hair loss (Gupta et al., 2026). Women appeared to be disproportionately affected (Gupta et al., 2026).

A separate systematic review published on PMC similarly identified telogen effluvium and androgenetic alopecia as the predominant hair loss subtypes associated with GLP-1 medications, and noted the clinical evidence remains somewhat limited, potentially due to underreporting (Systematic Review, PMC, 2026).

A pharmacovigilance-focused review found reporting odds ratios of 1.24–2.46 for semaglutide and 0.83–1.73 for tirzepatide in adverse event databases — a positive signal, though the review noted that without direct head-to-head comparison it remains unclear whether one medication carries meaningfully more risk than the other (Branyiczky et al., 2026).

Why it happens: rapid weight loss as physiological stress

The most consistently proposed mechanism across the reviews is telogen effluvium — a type of diffuse hair shedding triggered by significant physiological stress on the body, including rapid weight loss, surgery, or major lifestyle change (Healthline, 2025). One dermatologist quoted in the coverage of the BMJ study noted that GLP-1-associated hair loss has a distinctive pattern: because the weight loss is often sustained over an extended period rather than a single event, the shedding can continue throughout the weight loss process rather than resolving after a few weeks, as more typical telogen effluvium does (Healthline, 2025).

Several contributing mechanisms have been proposed beyond weight loss stress alone, including (ScienceDirect, 2025; PMC, 2025):

Nutritional deficiencies from significantly reduced food intake, particularly of iron, zinc, vitamin D, and biotin — all well-recognised triggers for telogen effluvium in their own right.
Endocrine and hormonal changes, including possible effects on thyroid hormone signalling, which plays an essential role in healthy hair follicle function.
Insulin-like growth factor-1 (IGF-1) signalling disruption, a proposed but less well-established mechanism.
Androgen-mediated pathways that may unmask underlying androgenetic alopecia in people already predisposed to it.

The reassuring part: it's generally temporary

Across the available evidence, GLP-1-related hair loss is generally described as temporary, though regrowth can take time (Healthline, 2025). Reported shedding typically follows the telogen effluvium pattern — emerging several months after starting treatment or after a period of rapid weight reduction, and improving once the underlying trigger (the rate of weight loss, or a nutritional deficiency) is addressed (ScienceDirect, 2025).

What the evidence points to as helpful

Given that nutritional deficiency is one of the most consistently cited contributing mechanisms, the practical implication is fairly direct: adequate intake of protein, iron, zinc, vitamin D, and biotin during rapid weight loss is one of the more evidence-aligned steps available, alongside general nutritional optimisation as part of managing the shedding (ScienceDirect, 2025). Rate of weight loss also matters — since higher rates of weight loss are associated with higher rates of reported alopecia in trial data specifically, a more moderate, sustainable pace of loss is itself a protective factor (Sharma et al., 2025).

Why this connects directly to how you approach treatment

The pattern here should sound familiar: rapid, aggressive weight loss without adequate nutritional support shows up as a problem in more than one place — muscle loss, facial volume loss, and now hair shedding are all connected to the same underlying issue of the body being under significant nutritional and physiological stress during fast weight loss.

This is exactly why our While You're On It programme focuses on structured nutrition alongside your medication — ensuring protein and micronutrient intake stay adequate throughout treatment, rather than leaving your body to absorb the full physiological stress of rapid weight loss unsupported.

If hitting your daily nutrient targets is difficult on a reduced appetite, our Alongside Daily Support powder is formulated to help support protein and key micronutrient intake during treatment.

And because pace of weight loss is directly tied to hair loss risk in the trial data, our Coming Off It programme helps ensure the transition off treatment is managed carefully too, rather than compounding the physiological stress further.

If you're noticing hair thinning and want a tailored nutritional review alongside your prescriber's guidance, our 1:1 coaching is available to help.

The bottom line

Hair thinning on GLP-1 medications is a real, evidence-documented effect — not a rumour — with trial data showing measurably elevated rates, particularly at higher doses and with greater total weight loss. The leading explanation is telogen effluvium triggered by the physiological stress of rapid weight loss, often compounded by nutritional deficiencies from reduced intake. The good news, consistently across the evidence, is that it's generally temporary and closely tied to factors — nutrition and pace of weight loss — that are genuinely within your control.

This article is for general information and isn't a substitute for medical advice. If you're experiencing significant hair loss, speak to your prescriber or a dermatologist to rule out other contributing causes.

References

Branyiczky, M., et al. (2026). Effects of GLP-1 receptor agonists on hair loss and regrowth: A systematic review. International Journal of Dermatology. https://onlinelibrary.wiley.com/doi/10.1111/ijd.70133

Gupta, A. K., Teasell, E. M., Economopoulos, V., & Mirmirani, P. (2026). GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. SAGE Journals. https://journals.sagepub.com/doi/10.1177/00368504261444578

Healthline. (2025, August 8). Hair loss from GLP-1 drugs is very real, study finds. How to treat it. https://www.healthline.com/health-news/glp-1-drugs-may-cause-hair-loss-treatment

ScienceDirect. (2025, June 19). Alopecia areata following semaglutide treatment for weight loss: A case report. https://www.sciencedirect.com/science/article/pii/S2352512625002644

Sharma, R., et al. (2025). Risk of hair loss with semaglutide for weight loss. medRxiv. https://www.medrxiv.org/content/10.1101/2025.02.23.25322568.full.pdf

Systematic Review. (2026). Hair loss associated with glucagon-like peptide-1 (GLP-1) receptor agonist use: A systematic review. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12530271/

(2025). Alopecia and semaglutide: Connecting the dots for patient safety. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909624/